{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"70.9","upperLimit":"87.3","value":"80.6"},{"groupId":"OG001","lowerLimit":"80.2","upperLimit":"93.5","value":"88.5"}]}],"title":"24 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.5","upperLimit":"82.5","value":"74.8"},{"groupId":"OG001","lowerLimit":"68.4","upperLimit":"85.5","value":"78.3"}]}],"title":"36 Months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.3","upperLimit":"76.1","value":"67.3"},{"groupId":"OG001","lowerLimit":"68.4","upperLimit":"85.5","value":"78.3"}]}],"title":"48 Months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"Percentage of participants who were event-free based on Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants diagnosed with WM with mutated MYD88 gene received 420 mg ibrutinib once daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG000","title":"Arm A: Ibrutinib"},{"description":"Participants diagnosed with WM with mutated MYD88 gene received 160 mg zanubrutinib twice daily orally until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor","id":"OG001","title":"Arm B: Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)","title":"PFS as Assessed by the Investigator: Event-Free Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}